Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5273009
Max Phase: Preclinical
Molecular Formula: C41H58O13
Molecular Weight: 758.90
Associated Items:
ID: ALA5273009
Max Phase: Preclinical
Molecular Formula: C41H58O13
Molecular Weight: 758.90
Associated Items:
Canonical SMILES: CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@H](O[C@H]2CC[C@]34C[C@]35CC(=O)[C@]3(C)[C@H]6[C@H](C)C[C@]7(OC(O)[C@@]8(C)O[C@@H]78)O[C@H]6C[C@@]3(C)[C@@H]5CC[C@H]4C2(C)C)OC[C@H]1OC(C)=O
Standard InChI: InChI=1S/C41H58O13/c1-19-14-41(33-38(9,53-33)34(46)54-41)52-23-15-36(7)26-11-10-25-35(5,6)28(12-13-39(25)18-40(26,39)16-27(45)37(36,8)29(19)23)51-32-31(50-22(4)44)30(49-21(3)43)24(17-47-32)48-20(2)42/h19,23-26,28-34,46H,10-18H2,1-9H3/t19-,23+,24-,25+,26+,28+,29+,30+,31-,32+,33-,34?,36+,37-,38+,39-,40+,41-/m1/s1
Standard InChI Key: NVEQPFOIYVPQSC-NYFOCMNHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 758.90 | Molecular Weight (Monoisotopic): 758.3877 | AlogP: 4.38 | #Rotatable Bonds: 5 |
Polar Surface Area: 165.65 | Molecular Species: NEUTRAL | HBA: 13 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 13 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.10 | CX Basic pKa: | CX LogP: 4.19 | CX LogD: 4.19 |
Aromatic Rings: 0 | Heavy Atoms: 54 | QED Weighted: 0.18 | Np Likeness Score: 2.81 |
1. Zhang H, Chen Y, Huang S, Xiao WW, Qiu MH, Shao LD, Chen CH, Li D.. (2023) Development of actein derivatives as potent anti-triple negative breast cancer agents., 89 [PMID:37121522] [10.1016/j.bmcl.2023.129307] |
Source(1):